Skip to main content

Table 3 Antibiotic susceptibilitya patterns and the related antibiotic resistance genes in the seven Vibrio furnissii strains

From: Virulence, antibiotic resistance phenotypes and molecular characterisation of Vibrio furnissii isolates from patients with diarrhoea

Antibiotic1

(µg/mL)

VFBJ01

VFBJ02

VFBJ03

VFBJ04

VFBJ05

VFBJ06

VFBJ07

β-lactam/β-lactamase inhibitor combinations

AMP

16 (I)

64 (R)

16 (I)

16 (I)

16 (I)

32 (R)

16 (I)

AMS

16/8 (I)

16/8 (I)

16/8 (I)

16/8 (I)

8/4 (S)

16/8 (I)

16/8 (I)

Cephems

CFZ

16 (R)

32 (R)

16 (R)

16 (R)

8 (R)

32 (R)

32 (R)

CAZ

1 (S)

2 (S)

0.5 (S)

1 (S)

0.5 (S)

1 (S)

0.5 (S)

FEP

1 (S)

8 (I)

1 (S)

1 (S)

1 (S)

1 (S)

1 (S)

AZM

2 (S)

8 (I)

< 1 (S)

2 (S)

2 (S)

1< (S)

< 1 (S)

Aminoglycosides

AMI

< 4 (S)

< 4 (S)

< 4 (S)

< 4 (S)

< 4 (S)

< 4 (S)

< 4 (S)

GEN

< 1 (S)

< 1 (S)

< 1 (S)

< 1 (S)

< 1 (S)

< 1 (S)

< 1 (S)

STR

> 32 (R)

8 (S)

16 (I)

16 (I)

> 32 (R)

8 (S)

> 32 (R)

Aminoglycoside resistance genes

StrA

+

-

-

-

+

-

+

StrB

+

-

-

-

+

-

+

aph (3’’)-Ib

+

-

-

-

-

-

+

aph (6)-Id

+

-

-

-

+

-

+

Fluoroquinolones

CIP

0.125 (S)

0.25 (S)

0.06 (S)

< 0.03 (S)

0.125 (S)

0.125 (S)

0.125 (S)

LEV

0.5 (S)

0.5 (S)

0.25 (S)

< 0.125 (S)

0.25 (S)

0.25 (S)

0.25 (S)

Fluoroquinolone resistance gene

aac (6’)-IIa

-

-

-

-

-

-

+

Carbapenems

IMI

2 (I)

> 8 (R)

2 (I)

2 (I)

2 (I)

2 (I)

2 (I)

MEM

0.25 (S)

4 (R)

0.25 (S)

0.125 (S)

0.125 (S)

0.25 (S)

0.125 (S)

Tetracyclines

TET

32 (R)

16 (R)

2 (S)

4 (S)

16 (R)

8 (I)

32 (R)

DOX

8 (I)

2 (S)

2 (S)

2 (S)

4 (S)

2 (S)

8 (I)

Tetracycline resistance genes

tetA

-

-

-

-

+

-

+

tetB

-

-

-

-

-

-

+

tetD

-

-

-

-

-

-

-

tetR

-

-

-

-

+

-

+

Phenicols

       

CHL

8 (S)

< 2 (S)

< 2 (S)

< 2 (S)

16 (I)

< 2 (S)

8 (S)

Phenicol resistance genes

floR

-

-

-

-

+

-

+

Folate pathway inhibitors

SUL

128 (S)

64 (S)

< 32 (S)

128 (S)

128 (S)

< 32 (S)

128 (S)

SXT

> 8/152 (R)

< 0.25/4.75 (S)

< 0.25/4.75 (S)

< 0.25/4.75 (S)

< 0.25/4.75 (S)

< 0.25/4.75 (S)

< 0.25/4.75 (S)

SUL resistance genes

Sul1

-

-

-

-

-

-

+

Sul2

+

-

-

-

+

-

+

Macrolides

AZI

< 2 (S)

< 2 (S)

< 2 (S)

< 2 (S)

< 2 (S)

< 2 (S)

< 2 (S)

  1. 1R: Resistant; I: Intermediate; S: Sensitive; AMP: Ampicillin; AMS: ampicillin/sulbactam; CFZ: cefazolin; CAZ: ceftazidime; FEP: cefepime; AZM: aztreonam; AMI: amikacin; GEN: gentamicin; STR: streptomycin; CIP: ciprofloxacin; LEV: levofloxacin; IMI: imipenem; MEM: meropenem; TET: tetracycline; DOX: doxycycline; CHL: chloramphenicol; SUL: sulphonamides; SXT: trimethoprim–sulfamethoxazole; AZI: azithromycin
  2. 2 Most breakpoints for defining susceptibility (µg/mL) are based on the CLSI M45-A3 standards for Vibrio spp. The breakpoints of AZM and DOX are based on the CLSI M100-ED33 criteria for the Enterobacteriaceae family. The breakpoint of AZI (S ≤ 2) is based on the CLSI M45-A3 standards for V. cholerae. The breakpoint of STR (S ≤ 4, I = 8, R ≥ 16) is based on the CLSI M45-A3 standards for Yersinia pestis
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us